Abstract P2-01-02: Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial

Jaeger, Bas; Rack, B; Andergassen, Ulrich; Neugebauer, Jörg; Melcher, C; Scholz, Christian W.; Hagenbeck, Carsten; Schueller, Katharina; Lorenz, Ralf; Decker, Thomas; Heinrich, Georg; Fehm, T; Schneeweiß, Andreas; Lichtenegger, W.; Beckmann, MW; Pantel, Klaus; Sommer, H.; Friese, Klaus

doi:10.1158/0008-5472.sabcs12-p2-01-02

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 – 42 The adjuvant phase III SUCCESS-B trial of early HER2 + breast cancer assessed baseline CTCs; patients were considered to have HER2 + CTCs if they had 1 or more detectable CTC with strong staining. 43 Results showed a discordance similar to that seen in other studies; of the 257 patients with HER2 + breast cancer with detectable CTCs, only 57.2% were determined to have HER2 + CTCs and 21.4% were questionable (having moderate HER2 staining). Data are pending on survival and the potential role of HER2 + CTCs in determining treatment efficacy.…”

Section: Prognostic and Predictive Value Of Ctc Detectionsupporting

confidence: 78%

Analysis of Circulating Tumor Cells in Breast Cancer

Eroglu¹,

Fielder²

2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Over the past few decades, substantial progress has been made in the diagnosis and treatment of breast cancer. Early identification of relapsed and metastatic disease has been a primary focus of ongoing research. Circulating tumor cells (CTCs) are implicated as harbingers of metastases. With advances in detection technologies, CTCs offer the option for real-time liquid biopsies. Methods to identify CTCs in the bloodstream by physical or biochemical properties, although feasible, still require improvements to promote widespread, reproducible use. Sufficient data support enumeration and assessment of changes in the number of CTCs as prognostic indicators, but controversy around their predictive utility for selecting treatments remains. As the technology to detect CTCs and characterize their heterogeneous molecular profile evolves, additional information will likely be obtained to guide targeted and individualized therapies.

show abstract

Section: Prognostic and Predictive Value Of Ctc Detectionsupporting

confidence: 78%

Analysis of Circulating Tumor Cells in Breast Cancer

Eroglu¹,

Fielder²

2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

show abstract

“…Pantel et al have shown that the HER2 status in CTCs varies with respect to the primary tumor. 39 Specifically, HER2+ CTCs may be observed in ∼30% of samples obtained from HER2-origin. 40 DNA fluorescence in situ hybridization (FISH) was carried out to evaluate the HER2 status of isolated CTCs.…”

Section: Fish Analysismentioning

confidence: 99%

“…This is in accordance with previous findings that heterogeneity of the HER2 status is evident in CTCs as compared to the primary tumor. 39…”

Section: Fish Analysismentioning

confidence: 99%

Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

et al. 2014

View full text Add to dashboard Cite

The enumeration and characterization of circulating tumor cells (CTCs), found in the peripheral blood of cancer patients, provide a potentially accessible source for cancer diagnosis and prognosis. This work reports on a novel spiral microfluidic device with a trapezoidal cross-section for ultra-fast, label-free enrichment of CTCs from clinically relevant blood volumes. The technique utilizes the inherent Dean vortex flows present in curvilinear microchannels under continuous flow, along with inertial lift forces which focus larger CTCs against the inner wall. Using a trapezoidal cross-section as opposed to a traditional rectangular cross-section, the position of the Dean vortex core can be altered to achieve separation. Smaller hematologic components are trapped in the Dean vortices skewed towards the outer channel walls and eventually removed at the outer outlet, while the larger CTCs equilibrate near the inner channel wall and are collected from the inner outlet. By using a single spiral microchannel with one inlet and two outlets, we have successfully isolated and recovered more than 80% of the tested cancer cell line cells (MCF-7, T24 and MDA-MB-231) spiked in 7.5 mL of blood within 8 min with extremely high purity (400-680 WBCs mL(-1); ~4 log depletion of WBCs). Putative CTCs were detected and isolated from 100% of the patient samples (n = 10) with advanced stage metastatic breast and lung cancer using standard biomarkers (CK, CD45 and DAPI) with the frequencies ranging from 3-125 CTCs mL(-1). We expect this simple and elegant approach can surmount the shortcomings of traditional affinity-based CTC isolation techniques as well as enable fundamental studies on CTCs to guide treatment and enhance patient care.

show abstract

“…terion was the HER2-negative nature of the primary tumour [60]. In total 6.9 % of the patients exhibited CTC.…”

Section: Number Of Events (%)mentioning

confidence: 98%

“…B. HER2-negative Patientinnen im Rahmen der Tumorprogression HER2-positive Metastasen entwickeln. Aus diesem Grund wurde in der SUCESS-C-Studie, deren Einschlusskriterium HER2-Negativität des Primärtumors war, der HER2-Status der zirkulierenden Tumorzellen (CTC) als potenzieller Ausgangspunkt einer späteren Metastasierung untersucht [60]. Insgesamt wiesen 6,9 % der Patientinnen CTC auf.…”

Section: Her2-status Zirkulierender Tumorzellen Im Rahmen Der Successunclassified

Breast Cancer 2013 - Interpretation of New and Known Data

Lux

Maass

Schütz

et al. 2013

Geburtsh Frauenheilk

View full text Add to dashboard Cite

The treatment options and characteristics for therapeutic decisions for patients with primary and advanced breast cancer are becoming more and more numerous. New targeted therapies in combination with established chemotherapy regimens are expending the spectrum but potentially promising combinations do not also give a better result. The latest data from pharmacogenomics point to prognosis and predictive factors that take not only the properties of the tumour but also the hereditary genetic features of the patient into account. Current therapy decisions are thus based on a combination of classical clinical and modern molecular biomarkers. Health-economic aspects are also being taken into account more often, so that health-political considerations may also play a part. The present review article summarises parts of the results presented at the 2012 San Antonio Breast Cancer Symposia (SABCS), ESMO 2012 and St.?Gallen 2013 together with new and important publications on the prevention of and therapy for breast cancer.

show abstract

Abstract P2-01-02: Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial

Cited by 3 publications

References 0 publications

Analysis of Circulating Tumor Cells in Breast Cancer

Analysis of Circulating Tumor Cells in Breast Cancer

Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

Breast Cancer 2013 - Interpretation of New and Known Data

Contact Info

Product

Resources

About